We thank van den Broek et al. [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394276 | PMC |
| http://dx.doi.org/10.3390/healthcare9081027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How to stent the ureter after kidney transplantation in children?-A comparison of two methods of urinary drainage.
Pediatr Transplant
February 2018
Department of Pediatric Nephrology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Ureteral stenting after pediatric renal transplantation serves to prevent obstruction and urinary leakage, but can also cause complications. This study compares the complication rates of both methods. Data were retrospectively collected at Erasmus MC, Rotterdam, the Netherlands (splint group, n = 61) and Hospital for Sick Children, Toronto, Canada (JJ catheter group, n = 50).
View Article and Find Full Text PDFThe Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Clin J Am Soc Nephrol
May 2015
Department of Medicine, Stanford University School of Medicine, Palo Alto, California;
Background And Objectives: The calcimimetic cinacalcet reduced the risk of death or cardiovascular (CV) events in older, but not younger, patients with moderate to severe secondary hyperparathyroidism (HPT) who were receiving hemodialysis. To determine whether the lower risk in younger patients might be due to lower baseline CV risk and more frequent use of cointerventions that reduce parathyroid hormone (kidney transplantation, parathyroidectomy, and commercial cinacalcet use), this study examined the effects of cinacalcet in older (≥65 years, n=1005) and younger (<65 years, n=2878) patients.
Design, Setting, Participants, & Measurements: Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) was a global, multicenter, randomized placebo-controlled trial in 3883 prevalent patients on hemodialysis, whose outcomes included death, major CV events, and development of severe unremitting HPT.
Cost Effectiveness Analysis Evaluating Factor Viii As Primary Prophylaxis Treatment for Patients With Severe Haemophilia A In the Netherlands.
Value Health
November 2014
PANAXEA, Enschede, The Netherlands.
Current and Future Costs of Osteoporotic Fractures in the Netherlands.
Value Health
November 2014
Erasmus University Rotterdam, Rotterdam, The Netherlands.
Amyotrophic lateral sclerosis (ALS) is the third most common adult-onset neurodegenerative disease. Individuals with ALS rapidly progress to paralysis and die from respiratory failure within 3 to 5 years after symptom onset. Epidemiological factors explain only a modest amount of the risk for ALS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!